Skip to main content

Table 2 Lymphoma entities

From: The value of complete remission according to positron emission tomography prior to autologous stem cell transplantation in lymphoma: a population-based study showing improved outcome

  N OS LSS PFS
2 y 5y 10y P 2y 5y 10y P 2y 5y 10y P
All lymphomas 521 74% 66% 56%   82% 76% 70%   64% 52% 42%  
 Primary aggressive B-cell lymphomas 121 59% 53% 47%   67% 64% 56%   52% 45% 41%  
  DLBCL or high-grade B-cell lymphoma 105 59% 52% 44%   68% 64% 55%   50% 42% 38%  
  Not-DLBCL or high-grade B-cell lymphoma 16 60% 60% 60% 0.28 64% 64% 64% 0.55 61% 61% 61% 0.14
   FL grade 3B 2             
   Burkitt lymphoma 3             
   PTLD 2             
   PMBCL or greyzone lymphoma 3             
   Plasmablastic lymphoma 5             
   Lymphomatoid granulomatosis grade III 1             
 Upfront patients 7 86% 86% 86%   100% 100% 100%   86% 86% 86%  
  Relapsed/refractory patients 114 58% 51% 44% 0.19 65% 62% 53% 0.070 50% 43% 38% 0.09
 Transformed B-cell lymphomas 107 71% 63% 52%   78% 69% 64%   59% 42% 35%  
  Transformed FL 72 76% 71% 56%   81% 75% 68%   65% 48% 38%  
  Transformed not-FL 35 61% 41% 41% 0.22 73% 49% 49% 0.35 48% 30% 30% 0.28
   Transformed MZL 18             
   Transformed CLL/SLL (Richter) 5             
   Transformed WM 3             
   Transformed NLPHL 2             
   Transformed indolent B-cell lymphoma 7             
  Upfront patients 28 92% 92% 92%   95% 95% 95   68% 55% 41%  
  Relapsed/refractory patients 79 64% 54% 41% 0.006 73% 61% 55% 0.009 55% 38% 33% 0.13
  Primary and transformed aggressive B-cell lymphomas 228 64% 58% 50%   72% 67% 60%   55% 44% 39%  
   Upfront patients 35 90% 90% 90%   96% 96% 96%   72% 63% 54%  
   Relapsed/refractory patients 193 60% 53% 44% 0.002 68% 63% 54% 0.001 52% 42% 37% 0.028
 Indolent B-cell lymphomas 49 80% 59% 44%   90% 75% 65%   60% 45% 26%  
  FL grade 1-3A 39 78% 57% 43%   88% 76% 69%   60% 44% 31%  
  Not-FL grade 1-3A 10 89% 63% 51% 0.55 100% 71% 57% 0.24 57% 46% 11% 0.48
   MZL 1             
   CLL/SLL 6             
   WM 1             
   NLPHL 2             
  All indolent lymphomas 156 74% 61% 48%   82% 71% 64%   59% 43% 31%  
   Not transformed 49 80% 59% 44%   90% 75% 65%   60% 45% 26%  
   Transformed 107 71% 63% 52% 0.77 78% 69% 64% 0.65 59% 42% 35% 0.77
  All follicular lymphomas 111 77% 65% 50%   83% 75% 68%   63% 47% 35%  
   Not transformed 39 78% 57% 43%   88% 76% 69%   60% 44% 31%  
   Transformed 72 76% 71% 56% 0.58 81% 75% 68% 0.63 65% 48% 38% 0.69
 Mantle cell lymphoma 99 86% 75% 73%   91% 82% 82%   80% 62% 43%  
  Classical 83 90% 78% 78%   95% 86% 86%   84% 67% 47%  
   Non-classical 16 66% 58% 43% 0.021 70% 62% 62% 0.025 61% 37% 18% 0.005
   Blastic 9             
   Pleomorphic or P53+ or Ki67 > 60% 7             
  Upfront patients 87 90% 78% 78%   93% 84% 84%   83% 66% 45%  
  Relapsed/refractory patients 12 58% 49% 32% 0.006 81% 67% 67% 0.30 58% 40% 40% 0.054
 T-cell lymphomas 85 74% 69% 53%   83% 79% 71%   65% 54% 45%  
  PTCL 78 79% 73% 56%   87% 83% 74%   70% 58% 48%  
  Non-PTCL 7 18% 18% ND 0.004 25% 25% ND 0.013 0% 0% 0% 0.002
   Sézary/ATLL 3             
   ENKTCL 4             
   PTCL, ALCL 25 79% 79% 74%   91% 91% 91%   80% 75% 70%  
   PTCL, non-ALCL 53 78% 69% 41% 0.08 85% 78% 63% 0.09 65% 47% 33% 0.023
   AITL/FHTCL 29             
   PTCL-NOS 17             
   EATCL/HSTCL/SPTCL/Lennert 7             
   Upfront PTCL patients 56 81% 75% 67%   86% 80% 71%   70% 60% 55%  
   Relapsed/refractory PTCL patients 22 73% 68% 39% 0.07 89% 89% 80% 0.44 68% 54% 38% 0.21
 Classical Hodgkin lymphoma 60 85% 83% 74%   92% 90% 90%   71% 66% 60%  
  1. Abbreviations: OS overall survival, LSS lymphoma-specific survival, PFS progression-free survival, DLBCL diffuse large B-cell lymphoma, FL follicular lymphoma, PTLD post-transplantation lymphoproliferative disorder, PMBCL primary mediastinal B-cell lymphoma, MZL marginal zone lymphoma, CLL chronic lymphocytic leukemia, SLL small lymphocytic lymphoma, WM Waldenström macroglobulinemia, NLPHL nodular lymphocyte-predominant Hodgkin lymphoma, PTCL peripheral T-cell lymphoma, ALCL anaplastic large cell lymphoma, AITL angioimmunoblastic T-cell lymphoma, FHTCL follicular helper T-cell lymphoma, EATCL enteropathy-associated T-cell lymphoma, HSTCL hepatosplenic T-cell lymphoma, SPTCL subcutaneous panniculitis-like T-cell lymphoma, ATLL adult T-cell leukemia/lymphoma, ENKTCL extranodal NK/T-cell lymphoma, nasal type